Purpose of Review <p>Non-tuberculous mycobacteria (NTM) infections are challenging to recognize, diagnose, and manage, particularly in lung transplant recipients. The aim of this review is to provide recommendations for diagnosis, treatment (including key drug-drug interactions of antimycobacterial agents and immunosuppressants), and long-term management of NTM infections in lung transplant recipients.</p> Recent Findings <p>Two systematic meta-analyses, both published in 2023, analyzed NTM infection in lung transplant recipients, and both found that NTM disease was associated with higher mortality after lung transplantation. These findings underscore the importance of future study in this field. Clinicians should be cognizant of novel effective antimycobacterial agents, such as omadacycline for rapid growing mycobacteria.</p> Summary <p>NTM infections pose a significant threat to lung transplant recipients, but these infections can be managed effectively in medical centers with experience in treating mycobacteria. The key management points are to consider all potential drug-drug interactions, consider the limitations of in vitro susceptibility testing, consider utilization of new antimycobacterial agents, and to consider close monitoring of patient’s symptoms and culture results.</p>